Zobrazeno 1 - 10
of 86
pro vyhledávání: '"John-William Sidhom"'
Autor:
Shuming Chen, Tracee L. McMiller, Abha Soni, Farah Succaria, John-William Sidhom, Laura C. Cappelli, Livia A. Casciola-Rosen, Isaac R. Morales, Preethi Sankaran, Alan E. Berger, Julie Stein Deutsch, Qingfeng C. Zhu, Robert A. Anders, Jody E. Hooper, Drew M. Pardoll, Evan J. Lipson, Janis M. Taube, Suzanne L. Topalian
Publikováno v:
Journal of Translational Medicine, Vol 22, Iss 1, Pp 1-12 (2024)
Abstract Background Tumor regression following immune checkpoint blockade (ICB) is often associated with immune-related adverse events (irAEs), marked by inflammation in non-cancerous tissues. This study was undertaken to investigate the functional r
Externí odkaz:
https://doaj.org/article/44edc95deb6444eabbd3e50a4991237d
Autor:
Joel Kidman, Rachael M. Zemek, John-William Sidhom, Debora Correa, Nicola Principe, Fezaan Sheikh, Vanessa S. Fear, Catherine A. Forbes, Abha Chopra, Louis Boon, Ayham Zaitouny, Emma de Jong, Robert A. Holt, Matt Jones, Michael J. Millward, Timo Lassmann, Alistair R.R. Forrest, Anna K. Nowak, Mark Watson, Richard A. Lake, W. Joost Lesterhuis, Jonathan Chee
Publikováno v:
OncoImmunology, Vol 13, Iss 1 (2024)
ABSTRACTImmune checkpoint therapy (ICT) causes durable tumour responses in a subgroup of patients, but it is not well known how T cell receptor beta (TCRβ) repertoire dynamics contribute to the therapeutic response. Using murine models that exclude
Externí odkaz:
https://doaj.org/article/f60545e051804f9796499b61db90824e
Autor:
Padmanee Sharma, Seunghee Kim-Schulze, Justin David, John-William Sidhom, Sacha Gnjatic, Guray Akturk, Matthew Galsky, Saurabh Gupta, Jonathan Anker, Sudeh Izadmehr
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/a87f061d3d274b8da3f06b3089d13db9
Autor:
Padmanee Sharma, Seunghee Kim-Schulze, Justin David, John-William Sidhom, Sacha Gnjatic, Guray Akturk, Matthew Galsky, Saurabh Gupta, Jonathan Anker, Sudeh Izadmehr
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/3e6abb5815e349cb8de4229214235bd1
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-8 (2021)
Abstract SARS-CoV-2 infection is characterized by a highly variable clinical course with patients experiencing asymptomatic infection all the way to requiring critical care support. This variation in clinical course has led physicians and scientists
Externí odkaz:
https://doaj.org/article/ca8b01617b884c0dbc22dd42758dab8e
Autor:
John-William Sidhom, Ingharan J. Siddarthan, Bo-Shiun Lai, Adam Luo, Bryan C. Hambley, Jennifer Bynum, Amy S. Duffield, Michael B. Streiff, Alison R. Moliterno, Philip Imus, Christian B. Gocke, Lukasz P. Gondek, Amy E. DeZern, Alexander S. Baras, Thomas Kickler, Mark J. Levis, Eugene Shenderov
Publikováno v:
npj Precision Oncology, Vol 5, Iss 1, Pp 1-8 (2021)
Abstract Acute promyelocytic leukemia (APL) is a subtype of acute myeloid leukemia (AML), classified by a translocation between chromosomes 15 and 17 [t(15;17)], that is considered a true oncologic emergency though appropriate therapy is considered c
Externí odkaz:
https://doaj.org/article/dd046aeb33da4cd3974afb7aa84c2bbd
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-12 (2021)
The advent of high-throughput T-cell receptor sequencing has allowed for the rapid and thorough characterization of the adaptive immune response. Here the authors show how deep learning can reveal both descriptive and predictive sequence concepts wit
Externí odkaz:
https://doaj.org/article/c4e3c2b9c49b4aa788292791fd3cc408
Autor:
Drew M Pardoll, Evan Lipson, John-William Sidhom, Karim Boudadi, Robert Anders, Dung T Le, Luis A Diaz, Nicolas Llosa, Janis Taube, Lingling Chen, Teniola F Oke, Christian F Meyer, Laurene S Cheung, Thomas B Schaffer, Jillian T Ngo, John McMahon Gross, Holly Kemberling
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 6 (2021)
Undifferentiated pleomorphic sarcoma (UPS), an aggressive soft-tissue sarcoma of adults, has been characterized by low tumor mutational burden (TMB) and high copy number alterations. Clinical trials of programmed death-1 (PD-1) blockade in UPS have r
Externí odkaz:
https://doaj.org/article/49dd5e69ccc04ef2b5cc0e561cbddcbd
Autor:
Kellie N. Smith, Nicolas J. Llosa, Tricia R. Cottrell, Nicholas Siegel, Hongni Fan, Prerna Suri, Hok Yee Chan, Haidan Guo, Teniola Oke, Anas H. Awan, Franco Verde, Ludmila Danilova, Valsamo Anagnostou, Ada J. Tam, Brandon S. Luber, Bjarne R. Bartlett, Laveet K. Aulakh, John-William Sidhom, Qingfeng Zhu, Cynthia L. Sears, Leslie Cope, William H. Sharfman, Elizabeth D. Thompson, Joanne Riemer, Kristen A. Marrone, Jarushka Naidoo, Victor E. Velculescu, Patrick M. Forde, Bert Vogelstein, Kenneth W. Kinzler, Nickolas Papadopoulos, Jennifer N. Durham, Hao Wang, Dung T. Le, Sune Justesen, Janis M. Taube, Luis A. Diaz, Julie R. Brahmer, Drew M. Pardoll, Robert A. Anders, Franck Housseau
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-8 (2019)
Abstract Background Several predictive biomarkers are currently approved or are under investigation for the selection of patients for checkpoint blockade. Tumor PD-L1 expression is used for stratification of non-small cell lung (NSCLC) patients, with
Externí odkaz:
https://doaj.org/article/1bbf8602f6f8428183fdc7d49f984cca
Autor:
John-William Sidhom, Craig Cummings
Publikováno v:
Cancer Research Communications. 3:501-509
Background: Tumor mutational burden (TMB) has been investigated as a biomarker for immune checkpoint blockade (ICB) therapy. Increasingly, TMB is being estimated with gene panel–based assays (as opposed to full exome sequencing) and different gene